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We investigated multidrug-resistant (MDR) Myco-
bacterium tuberculosis strains in Bangui, Central African
Republic. We found 39.6% with the same spoligotype and
synonymous single nucleotide polymorphism in the mutT1
gene. However, strains had different rpoB mutations
responsible for rifampin resistance. MDR strains in Bangui
may emerge preferentially from a single, MDR-prone family.
T
uberculosis (TB) is a major public health problem and
causes 2 million deaths each year. Ninety-five percent
of cases are in developing countries, where limited health-
care resources lead to incomplete case and contact tracing,
inadequate treatment, and as a consequence, to a larger
drug resistance problem (1,2). Multidrug-resistant TB
(MDRTB), defined as resistant to at least rifampin and iso-
niazid, is more difficult to treat and can cost 100× more
than susceptible TB; it is associated with a high death rate
in HIV-infected patients (3,4). MDRTB results from the
selection of MDR strains in patients who failed to com-
plete chemotherapy with the correct combination of drugs.
The typing of MDR strains can be used to describe trans-
mission and outbreaks, as shown by the identification of
MDR epidemics due to the Beijing/W family strains (5).
Other types, including Haarlem and Mycobacterium bovis
isolates, have been involved in MDR outbreaks (6,7).
Because MDR strains carry mutations in major metabolic
pathways, some researchers have suggested that they may
be less virulent and less transmissible (8); however, the
occurrence of epidemics involving these strains would
seem to contradict this suggestion. As with other MDR
bacterial species, they may have emerged from strains
more adapted to the local population (9). We have previ-
ously described variations in putative anti-mutator genes
in Beijing/W isolates that may have favored adaptive
mutations in this family of strains. The failure to show
mutator phenotypes in Beijing/W strains suggests that this
role may have been transient (10,11).
We studied MDRTB strains in Bangui, Central African
Republic (CAR), because little information has been col-
lected concerning MDRTB in sub-Saharan Africa. In
CAR, the incidence of TB is estimated to be 250 per
100,000 inhabitants, and 1.1% of cases are MDR (12). In
Bangui, ≈15% of the sexually active population is infected
with HIV. We spoligotyped MDR strains collected by the
Pasteur Institute of Bangui and looked for diversity in a
series of putative anti-mutator genes.
The Study
We studied 53 MDR M. tuberculosis strains isolated
from different patients between 1993 and 2001 at the
Bangui Pasteur Institute. Fourteen of these patients were
HIV positive, 30 were HIV negative, and 9 were of unde-
termined status. Epidemiologic enquiries did not show a
social link among patients (unpub. data). A non-MDR,
nonbiased control group, which included 263 M. tubercu-
losis and 2 M. bovis strains, was also studied. These strains
included all those from the cohort studied by Espinal et al.
(3) for which a subculture was obtained.
All 318 isolates were typed by using the spoligotyping
method previously described (13). Spoligotypes were
obtained for 283 (53 MDR and 230 non-MDR strains) of
the 318 isolates and were analyzed with BioNumerics soft-
ware (Applied Maths, Kortrijk, Belgium). Dendrograms
were constructed according to degree of similarity (Dice
coefficient) and comparison with known spoligotypes.
Seventy-nine different spoligotypes were identified: 55
included only a single strain, and 24 included 2–56 strains.
The 24 clusters were named A to X (online Appendix
Figure, available from http://www.cdc.gov/ncidod/EID/
vol12no09/06-0361-appG.htm).
The 53 MDR strains clustered in 8 clusters (Figure,
panel A). Twenty-five (47.2%) of 53 clustered in type E,
which has characteristics of the Tfamily (ancient M. tuber-
culosis strains with numerous spacers [14]). The 230
spoligotype patterns of non-MDR strains were grouped
into 22 clusters, and spoligotype E was not a major cluster
(Figure, panel B). Cluster Q contained the largest number
of strains. Its spoligotype is identical to the DB3 pattern
ST47 characteristic of the Haarlem family (15).
Spoligotypes 97%–99% identical with profiles characteris-
tic of the Haarlem family of strains represent 155 strains.
These observations confirm the predominance of the
Haarlem type in Africa. However, the Haarlem family was
not predominant in our collection of MDR isolates.
The clustering of MDR strains suggested an MDR out-
break; therefore, we looked for other characteristics in
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region, which was likely to be responsible for rifampin
resistance. Five variants were found among the 26 MDR
strains that constituted clusters E and F (Table): 9 had a
Ser-531 (TCG) to Leu (TTG) substitution; 8 and 5 strains
contained a substitution of His-526 (CAC) with Tyr (TAC)
and Arg (CGC), respectively; 3 had an Asp-516 (GAC) to
Val (GTC) variant; and 1 a Leu-533 (CTG) to Pro (CCG)
substitution. All these variations are in the rifampin resist-
ance-determining region frequently encountered in strains
with a rifampin-resistant phenotype (8). These variants
probably determine rifampin resistance and may have
occurred independently, not necessarily corresponding to
MDRTB transmission, even for strains of the same cluster
with the same change in rpoB. Indeed, sociodemographic
and epidemiologic characterization of the patients did not
show any links between these MDRTB cases. Therefore,
rifampin resistance seems to have been acquired independ-
ently and repeatedly by cluster E and F strains. To find a
way to reduce the dissemination of such strains likely to
generate MDR isolates, we characterized strains of cluster
E and F. In particular, we looked for single nucleotide
polymorphisms (SNPs) in the putative genes mutT1,
mutT2, mutT3, Rv3908, mutY, mutM, ada/alkA, and ogt.
Sequencing was performed as previously described (11).
With reference to published M. tuberculosis sequences, we
found 1 synonymous SNP in mutT1 corresponding to Val
265 (GTC) to Val (GTA). This SNP is only present in
strains of cluster E and strains 27 (cluster F), 28, and 29
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Figure. Strain distribution into various clusters observed among 53
spoligotyped multidrug-resistant (MDR) strains (A) and 230 spolig-
otyped non-MDR strains (B).and is absent from all strains in other clusters. Therefore,
these MDR strains are characterized by a spoligotype pat-
tern (ST 52 ± spacer 11 or 12 to 15 and ST 107) and the
presence of the mutT1 SNP 265.
MDR strains of clusters E and F and strains 28 and 29
(a single difference in spacers between E and F, strain 28
or 29) corresponded to 9 new cases and 19 patients who
had received previous treatment. MDR strains in other
clusters corresponded to 9 new cases, 15 previously treat-
ed patients, and 1 case for which no history was available
(3).
Conclusions
We used 2 types of markers to study the genetic diver-
sity of MDR M. tuberculosis strains isolated in Bangui:
spoligotyping and SNPs in a series of putative DNArepair
genes. Many MDR strains were clustered in 1 spoligotype
and carried the same SNP in the anti-mutator gene mutT1.
Indeed, 25 of the 53 MDR strains were in cluster E. Thirty-
two percent of these MDR strains were from new cases of
infection, and 40% were from HIV-infected patients. This
cluster was not a major cluster among the 265 non-MDR
isolates collected during a 5-month period. The same SNP
was found in all strains of cluster E and F tested and in 2
strains that differed by 1 spacer. These strains carry vari-
ants of rpoB that confer rifampin resistance, which implies
that these strains do not correspond to an MDR-TB out-
break. However, this finding is consistent with the possi-
bility that these strains represent an MDR-prone family,
members of which are often associated with MDR pheno-
types in Bangui. Detection of strains characterized by the
T family spoligotype and mutT1 SNP265 may be useful to
identify patients at risk of developing MDR-TB.
This article is dedicated to the memory of Eric Kassa-
Kelhembo, head of the mycobacterial laboratory in Institut
Pasteur of Bangui, who was killed during a mission in CAR with-
in the context of the fight against tuberculosis.
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